Next 10 |
2024-04-16 12:22:50 ET More on rare disease pharmas/biotechs Sarepta Therapeutics: Growth Trajectory Alters Trading Strategy Sarepta Therapeutics: Another 'Hold' Call Ahead Of Some Key Catalysts Ultragenyx Pharmaceutical Earnings: No Visible Path To Financial Success...
2024-04-02 14:22:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-03-13 11:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Inhibrx Reports Fourth Quarter and Fiscal Year 2023 Financial Results PR Newswire SAN DIEGO , Feb. 28, 2024 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a biopharmaceutical company with three clinical programs in development and a strong eme...
NEW YORK, NY / ACCESSWIRE / February 10, 2024 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Inhibrx, Inc. (NASDAQ: INBX)'s...
NEW YORK, NY / ACCESSWIRE / January 27, 2024 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to Inhibrx, Inc. (NASDAQ: INBX)'s sa...
NEW YORK, NY / ACCESSWIRE / January 26, 2024 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Kaman Corp. (NYSE:KAMN)'s sale t...
NEW YORK, NY / ACCESSWIRE / January 25, 2024 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Inhibrx, Inc. (NASDAQ:INBX)'s sa...
2024-01-24 09:00:58 ET Summary Sanofi acquires INBRX-101 from Inhibrx for $2.2 billion, targeting rare disease Alpha-1 Antitrypsin Deficiency (AATD). INBRX-101's monthly dosing offers a potential improvement over weekly treatments in AATD, with a novel AAT-Fc fusion approach. ...
2024-01-23 04:42:01 ET In a bid to strengthen its rare disease portfolio, Sanofi ( NASDAQ: SNY ) has agreed to acquire certain assets from biopharmaceutical company Inhibrx ( NASDAQ: INBX ) in a deal valued at up to $2.2B.... Read the full article on Seeking Alpha ...
News, Short Squeeze, Breakout and More Instantly...
Inhibrx Inc. Company Name:
INBX Stock Symbol:
NASDAQ Market:
2024-04-02 14:22:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
NEW YORK, March 27, 2024 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potenti...
NEW YORK, March 13, 2024 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potenti...